ClinicalTrials.gov
public full text
Public Domain
A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions
CB307 is a trispecific Humabody® targeting CD137; PSMA; and human serum albumin (HSA) undergoing Phase 1 assessment in patients with PSMA+ solid tumours. This sub study will assess the biodistribution of radiolabelled CB307 in patients with advanced and/or metastatic solid tumours that are PSMA+.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia#1089036
- Table 1_HIST1H2BJ is associated with poor prognosis and an immune-altered tumor microenvironment in glioma.xlsx#922335
- A contamination-adjusted tissue thrombopoietic framework identifies a clinically relevant CAF-myeloid niche in non-small cell lung cancer: a paired transcriptomic and survival study.#242256
- Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM#1171302
- A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer#1173550
Record · ID 831928
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive